The use of various insulin types was not linked to breast cancer risk in women with diabetes regardless of dosage, duration of use and tumor stage, a study in Diabetes Care indicated. Data showed the odds ratio of breast cancer after 3.2 years of insulin use was 1.04 for patients who used glargine, 1.23 for those who took lispro, 0.95 for those who used aspart and 0.81 for those on human insulin.

Related Summaries